METASTATIC COLORECTAL CANCER AND PREOPERATIVE ANTITUMOR THERAPY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hepatectomy is the only possible modality to give patients hope for cure for metastatic colorectal cancer; this requires maximum effort to achieve resectability. One of the most important ways for this is preoperative chemotherapy, where possible, by adding target drugs. Preoperative antitumor therapy has no negative impact on intraoperative parameters and postoperative course.

Full Text

Restricted Access

About the authors

M. Sekacheva

Acad. B.V. Petrovsky Russian Surgery Research Center

Email: sekach_rab@mail.ru

N. Bagmet

Acad. B.V. Petrovsky Russian Surgery Research Center

O. Sklpenko

Acad. B.V. Petrovsky Russian Surgery Research Center

References

  1. Ferlay J., Shin H., Bray F. et al. GLOBOCAN 2008,Version 1.2, Cancer Incidence and Mortality Worldwide. IARC CancerBase №10. URL: http://globocan. iarc.fr (accessed November 23, 2011).
  2. Nordlinger B., Sorbye H., Glimelius B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial // Lancet. - 2008; 371: 1007-17.
  3. Pozzo C., Basso M., Cassano A. et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients // Ann. Oncol. - 2004; 15: 933-9.
  4. Masi G., Loupakis F., Pollina L. et al. Longterm outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases // Ann. Surg. - 2009; 249 (3): 420.
  5. Folprecht G., Gruenberger T., Bechstein W. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial // Lancet Oncol. - 2010; 1: 38-47.
  6. Kesmodel S., Ellis L., Lin E. et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases // J. Clin. Oncol. - 2008; 26: 5254-60.
  7. Falcone A., Ricci S., Brunetti I. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest // J. Clin. Oncol. - 2007; 13: 1670-6.
  8. Ong J., Younossi Z. Epidemiology and natural history of NAFLD and NASH // Clin. Liver. Dis. - 2007; 11: 1-16.
  9. Cleary J., Tanabe K., Lauwers G. et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver // The Oncologist. - 2009; 14: 1095-105.
  10. Vauthey J., Pawlik T., Ribero D. et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic metastases // J. Clin. Oncol. - 2006; 24: 2065-72.
  11. Rubbia-Brandt L., Audard V, Sartoretti P. et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer // Ann. Oncol. - 2004; 15: 460-6.
  12. Scoggins C., Campbell M., Landry C. et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases // Ann. Surg. Oncol. - 2009; 16: 35-41.
  13. Spelt L., Hermansson L., Tingstedt B. et al. Influence of Preoperative Chemotherapy on the Intraoperative and Postoperative Course of Liver Resection for Colorectal Cancer Metastases // World J. Surg. - 2012; 36: 157-63.
  14. Narita M., Oussoultzoglou E., Fuchshuber P. et al. What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperat // Ann. Surg. Oncol. - 2012; 19 (8): 2526-38.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House